Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ADX10061

            Therapeutic Area: Neurology Product Name: ADX10061

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innosuisse

            Deal Size: $0.6 million Upfront Cash: Undisclosed

            Deal Type: Funding August 27, 2020


            CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.